IL-13 x IL-31
Assets acting on this target.
- Class
- Bispecific engineered attobody
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| ATTO-3712 | Attovia Therapeutics | IL-13 x IL-31 | Atopic Dermatitis | Ph 1 | Attovia Therapeutics is actively running a company-sponsored Phase 1 study of ATTO-3712 in healthy volunteers and atopic dermatitis patients, begun in late 2025 and updated as recently as May 2026. | source ↗ |